Adaptimmune is a clinical-stage biotechnology company with clinical trials ongoing for multiple proprietary SPEAR T-cells in solid tumor indications. Adaptimmune partners with industry leaders in all areas of its business.
We are passionate about our SPEAR T-cell therapies, and we are always looking for the right technology partnerships to deliver for people living with cancer.
The Company has alliances with a range of partners listed below.
Adaptimmune has a collaboration and license agreement with Alpine Immune Sciences, Inc., to develop next-generation SPEAR T-cell products.View Partner
Adaptimmune has signed a co-development and co-commercialization agreement with Astellas, through its wholly-owned subsidiary Universal Cells, Inc, to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.View Partner
Our agreement with Cell and Gene Therapy Catapult enables us to have our own dedicated GMP (Good Manufacturing Practices) vector manufacturing space in the UK.View Partner
We signed a collaboration agreement with the Center for Cancer Immune Therapy (CCIT-DK - based in Copenhagen) in 2020. CCIT is one of the leading academic centers in Europe involved in researching tumor infiltrating lymphocyte (TIL) therapies.View Partner
Adaptimmune entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group, to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.View Partner
We signed a major collaboration and license agreement in June 2014 for up to five programs including the first program, NY-ESO, which we transitioned to GSK in 2018.
On October 24, 2022, GSK notified Adaptimmune that they will transfer the NY-ESO cell therapy program and their rights to the PRAME program back to Adaptimmune. Timing and details regarding the transfer resulting from the termination of the agreement are still being negotiated. Link to press release.View Partner
Adaptimmune has engaged with The University of Texas MD Anderson Cancer Center since 2016 to expedite the development of novel adaptive T-cell therapies for multiple types of cancer.View Partner
Adaptimmune is working with Noile-Immune Biotech Inc. to co-develop next‑generation SPEAR T-cell products, incorporating Noile-Immune’s PRIME (PRoliferation Inducing and Migration Enhancing) technology.View Partner